These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 28797967)

  • 41. Mechanistic Studies of Viral Entry: An Overview of Dendrimer-Based Microbicides As Entry Inhibitors Against Both HIV and HSV-2 Overlapped Infections.
    Sepúlveda-Crespo D; Ceña-Díez R; Jiménez JL; Ángeles Muñoz-Fernández M
    Med Res Rev; 2017 Jan; 37(1):149-179. PubMed ID: 27518199
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Low-Cost Compound Lignosulfonic Acid (LA) Exhibits Broad-Spectrum Anti-HIV and Anti-HSV Activity and Has Potential for Microbicidal Applications.
    Gordts SC; Férir G; D'huys T; Petrova MI; Lebeer S; Snoeck R; Andrei G; Schols D
    PLoS One; 2015; 10(7):e0131219. PubMed ID: 26132818
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The AGMA1 poly(amidoamine) inhibits the infectivity of herpes simplex virus in cell lines, in human cervicovaginal histocultures, and in vaginally infected mice.
    Donalisio M; Quaranta P; Chiuppesi F; Pistello M; Cagno V; Cavalli R; Volante M; Bugatti A; Rusnati M; Ranucci E; Ferruti P; Lembo D
    Biomaterials; 2016 Apr; 85():40-53. PubMed ID: 26854390
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The traditional use of Vachellia nilotica for sexually transmitted diseases is substantiated by the antiviral activity of its bark extract against sexually transmitted viruses.
    Donalisio M; Cagno V; Civra A; Gibellini D; Musumeci G; Rittà M; Ghosh M; Lembo D
    J Ethnopharmacol; 2018 Mar; 213():403-408. PubMed ID: 29203273
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Carbosilane dendrons with fatty acids at the core as a new potential microbicide against HSV-2/HIV-1 co-infection.
    Guerrero-Beltrán C; Ceña-Diez R; Sepúlveda-Crespo D; De la Mata J; Gómez R; Leal M; Muñoz-Fernández MA; Jiménez JL
    Nanoscale; 2017 Nov; 9(44):17263-17273. PubMed ID: 29090302
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Emtricitabine/tenofovir disoproxil fumarate.
    Drugs R D; 2004; 5(3):160-1. PubMed ID: 15139777
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Design and evaluation of mucoadhesive vaginal tablets of tenofovir disoproxil fumarate for pre-exposure prophylaxis of HIV.
    Khan AB; Thakur RS
    Drug Dev Ind Pharm; 2018 Mar; 44(3):472-483. PubMed ID: 29082767
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A novel intravaginal ring to prevent HIV-1, HSV-2, HPV, and unintended pregnancy.
    Ugaonkar SR; Wesenberg A; Wilk J; Seidor S; Mizenina O; Kizima L; Rodriguez A; Zhang S; Levendosky K; Kenney J; Aravantinou M; Derby N; Grasperge B; Gettie A; Blanchard J; Kumar N; Roberts K; Robbiani M; Fernández-Romero JA; Zydowsky TM
    J Control Release; 2015 Sep; 213():57-68. PubMed ID: 26091920
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Establishment of HK-2 Cells as a Relevant Model to Study Tenofovir-Induced Cytotoxicity.
    Murphy RA; Stafford RM; Petrasovits BA; Boone MA; Valentovic MA
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28257038
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multipurpose prevention technologies: products in development.
    Friend DR; Clark JT; Kiser PF; Clark MR
    Antiviral Res; 2013 Dec; 100 Suppl():S39-47. PubMed ID: 24188708
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Factors Contributing to the Antiviral Effectiveness of Tenofovir.
    Murphy RA; Valentovic MA
    J Pharmacol Exp Ther; 2017 Nov; 363(2):156-163. PubMed ID: 28860352
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.
    Koenig HC; Mounzer K; Daughtridge GW; Sloan CE; Lalley-Chareczko L; Moorthy GS; Conyngham SC; Zuppa AF; Montaner LJ; Tebas P
    HIV Med; 2017 Jul; 18(6):412-418. PubMed ID: 28444867
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
    Margot N; Cox S; Das M; McCallister S; Miller MD; Callebaut C
    Antivir Ther; 2017; 22(5):443-446. PubMed ID: 28076335
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Change in Renal Function among HIV-Infected Koreans Receiving Tenofovir Disoproxil Fumarate-Backbone Antiretroviral Therapy: A 3-Year Follow-Up Study.
    Lee KH; Lee JU; Ku NS; Jeong SJ; Han SH; Choi JY; Song YG; Kim JM
    Yonsei Med J; 2017 Jul; 58(4):770-777. PubMed ID: 28540990
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression of Genes for Drug Transporters in the Human Female Genital Tract and Modulatory Effect of Antiretroviral Drugs.
    Hijazi K; Cuppone AM; Smith K; Stincarelli MA; Ekeruche-Makinde J; De Falco G; Hold GL; Shattock R; Kelly CG; Pozzi G; Iannelli F
    PLoS One; 2015; 10(6):e0131405. PubMed ID: 26102284
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Administration of tenofovir disoproxil fumarate-based antiretroviral therapy in an HIV-infected patient following unilateral nephrectomy.
    Biagi M; Badowski M; Chiampas T; Young J; Vaughn P; Shicker L; Patel M
    Int J STD AIDS; 2016 Aug; 27(9):808-11. PubMed ID: 26378193
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Etravirine inhibits ABCG2 drug transporter and affects transplacental passage of tenofovir disoproxil fumarate.
    Reznicek J; Ceckova M; Tupova L; Staud F
    Placenta; 2016 Nov; 47():124-129. PubMed ID: 27780535
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Alginate microbead-encapsulated silver complexes for selective delivery of broad-spectrum silver-based microbicides.
    Damelin LH; Fernandes MA; Tiemessen CT
    Int J Antimicrob Agents; 2015 Oct; 46(4):394-400. PubMed ID: 26184337
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.
    Gafni RI; Hazra R; Reynolds JC; Maldarelli F; Tullio AN; DeCarlo E; Worrell CJ; Flaherty JF; Yale K; Kearney BP; Zeichner SL
    Pediatrics; 2006 Sep; 118(3):e711-8. PubMed ID: 16923923
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tenofovir Inhibits Wound Healing of Epithelial Cells and Fibroblasts from the Upper and Lower Human Female Reproductive Tract.
    Rodriguez-Garcia M; Patel MV; Shen Z; Bodwell J; Rossoll RM; Wira CR
    Sci Rep; 2017 Apr; 8():45725. PubMed ID: 28368028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.